Navigation Links
Study Reaffirms Superiority of Trofile(TM) Assay
Date:12/19/2007

about the Company and its technology can be found on its web site at http://www.monogrambio.com.

Forward Looking Statements

Certain statements in this press release are forward-looking. These forward-looking statements include references to the demand for our Trofile Assay, the potential use of our Trofile Assay for patient selection for maraviroc, the size and timing of clinical trials utilizing our products, the outlook for maraviroc and our Trofile Assay, the number of patients each year in the U.S. who potentially could be candidates for new classes of HIV drugs such as maraviroc, expected protection provided by patents, possible regulation of Trofile and our other products by the FDA, and activities expected to occur in connection with the Pfizer collaboration. These forward- looking statements are subject to risks and uncertainties and other factors, which may cause actual results to differ materially from the anticipated results or other expectations expressed in such forward-looking statements. These risks and uncertainties include, but are not limited to: the risk that physicians may not use a molecular diagnostic for patient selection for maraviroc or other HIV drugs; whether larger confirmatory clinical studies will confirm the results of initial studies; risks related to the implementation of the collaboration with Pfizer; risks related to our ability to recognize revenue from activities under the collaboration with Pfizer; risks and uncertainties relating to the performance of our products; the growth in revenues; the size, timing and success or failure of any clinical trials for CCR5 inhibitors, entry inhibitors or integrase inhibitors; the risk that our Trofile Assay may not be utilized for patient use with maraviroc and other CCR5 inhibitors; our ability to successfully conduct clinical studies and the results obtained from those studies; our ability to establish reliable, high-vol
'/>"/>

SOURCE Monogram Biosciences, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
3. Kline Study: Better Brushing Habits Boost European Oral Care Sales
4. Evotec to Present Details of the Positive Phase II Study in Insomnia With EVT 201 at the Worldsleep07 Congress in Cairns/Australia
5. NASA study will help stop stowaways to Mars
6. New Study Findings Confirm CLEXANE(R)/LOVENOX(R) Long-Term Clinical Benefit in Patients Suffering From Acute Coronary Syndrome
7. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
8. Evotec Reports Details of the Positive Proof-of-Concept Phase II Study in Insomnia With EVT 201
9. Study Supports Use of GlycoMark Blood Test to Evaluate Therapy in Children with Diabetes
10. Quigley Corporation Releases Update on Quigley Pharmas Phase IIb Clinical Study of QR-333 in Diabetic Peripheral Neuropathy
11. Biodel Inc. Announces VIAject(TM) Phase II Meal Study Data at the 2007 European Association for the Study of Diabetes Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... EDISON, N.J. , Sept. 1, 2015  ContraVir ... focused on the development and commercialization of targeted antiviral ... Rodman & Renshaw 17 th Annual Global Investment ... taking place September 8-10, 2015 at The St. Regis ... James Sapirstein , Chief Executive ...
(Date:9/1/2015)... Poway, CA (PRWEB) , ... September 01, 2015 ... ... Equine Cervical Facet joint disease. , Equine cervical facet joint problems can ... joints gradually enlarge, and can cause impingement of nerve roots or of the ...
(Date:9/1/2015)... ... September 01, 2015 , ... ... Business Development, Asia Pacific. In this newly-created position, Gibbs will lead iLab’s business ... of iLab’s suite of tools. This entails not only introducing iLab to potential ...
(Date:8/31/2015)... ... August 31, 2015 , ... The Global Supply Chain ... management and resiliency practitioners with luminaries and thought leaders to advance the professional ... for their innovations and performance excellence. At that time its principle sponsor, ...
Breaking Biology Technology:ContraVir to Present at Rodman & Renshaw 17th Annual Global Investment Conference 2VetStem Biopharma Announces New Clinical Research Program for Equine Cervical Facet Joint Disease 2VetStem Biopharma Announces New Clinical Research Program for Equine Cervical Facet Joint Disease 3iLab Solutions Hires Gerard Gibbs, Director of Business Development, Asia Pacific 2iLab Solutions Hires Gerard Gibbs, Director of Business Development, Asia Pacific 3Global Supply Chain Resiliency Council Announces Incorporation and Web Site Launch 2Global Supply Chain Resiliency Council Announces Incorporation and Web Site Launch 3
... CRY ),a biomaterials, medical device and tissue ... 2008 Cardiac Allograft Symposium at its,corporate headquarters training ... will focus on current clinical outcomes, indications and,surgical ... the CryoValve(R) SG pulmonary human heart valves., ...
... Aida,Pharmaceuticals, Inc. (OTC Bulletin Board: AIDA) today ... controlling interest in Jiangsu,Institute of Microbiology Co., Ltd. ... the People,s Republic of China. JSIM,has several drugs ... its development pipeline. This acquisition is expected to ...
... United,Therapeutics Corporation (Nasdaq: UTHR ) announced today ... results before the open of market,on Thursday, May ... half-hour teleconference on Thursday,May 1, 2008, at 9:00 ... 1-800-603-1777, with international callers dialing 1-706-679-8129.,A rebroadcast of ...
Cached Biology Technology:CryoLife Conducts Surgeons Cardiac Allograft Symposium 2Aida Pharmaceuticals, Inc. Announces Completion of Research Institute Acquisition 2
(Date:8/12/2015)... 12, 2015  New research unveiled at Black ... phones to steal users, fingerprints. Information released today ... fingerprint scanners on mobile devices, making the security ... biometrics on mobile devices, HYPR Corp. recently released ... authentication systems with strong cryptographic security. More information ...
(Date:8/10/2015)... BOSTON and TELTOW, Germany ... SensoMotoric Instruments (SMI), a world leader in Eye ... the completion of its OEM Eye Tracking Platform for ... Eye Tracking Platform contains reference designs for seamless integration ... kiosk systems, virtual reality HMDs and augmented reality smart ...
(Date:8/6/2015)... BOSTON and TELTOW, Germany ... the 2015 Siggraph Conference, SensoMotoric Instruments (SMI) ... augmented reality , based on Epson,s Moverio ... eye tracking platform. With this new solution, unprecedented quality ... multi-modal, hands-free interaction with context-sensitive displays. For the first ...
Breaking Biology News(10 mins):HYPR Corp. Addresses Android Vulnerability That Exposes Ecosystem-wide Biometric Security Challenges 2HYPR Corp. Addresses Android Vulnerability That Exposes Ecosystem-wide Biometric Security Challenges 3SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 3SMI Shows First Eye Tracking Upgrade for Augmented Reality Glasses 2SMI Shows First Eye Tracking Upgrade for Augmented Reality Glasses 3
... 27 SAFC®, a member of the Sigma-Aldrich® Group ... investment program to expand its Lenexa, KS , ... seamless upstream and downstream production of dry powder media and ... designed to better serve the biopharmaceutical industry by creating ,Centers ...
... , April 27 Negotiations broke off early Tuesday morning between ... Professionals (PASNAP) following a 14-hour session.  Talks are expected to resume later today at ... Continued progress was reported, ... , , ...
... MDC ) today announced that its board of directors has declared a regular quarterly ... common stock.  The dividend will be paid on Wednesday, May 26, 2010 to ... , , ... , Since 1972, MDC,s subsidiary ...
Cached Biology News:SAFC(R) Announces $6.25 Million Expansion at Lenexa 'Center of Excellence' 2SAFC(R) Announces $6.25 Million Expansion at Lenexa 'Center of Excellence' 3SAFC(R) Announces $6.25 Million Expansion at Lenexa 'Center of Excellence' 4SAFC(R) Announces $6.25 Million Expansion at Lenexa 'Center of Excellence' 5M.D.C. Holdings Declares Quarterly Cash Dividend 2
... separation and fractionation of nucleic-acid ... nuclei from cytosolic proteins A ... greatly facilitating study of low-abundance ... acid binding proteins (e.g., transcription ...
... was developed for culturing hybrid cells that ... consists of doubling the amino acids and ... concentrations have been altered as well. This ... liter, which may render it unsuitable for ...
... is an 18 amino acid synthetic peptide whose sequence corresponds to ... peptide is (amino to carboxy terminus): M(1) - A - S ... A - S - P - R - D - A ... peptide may be used for neutralization and control experiments with the ...
... EpiTect Bisulfite Kit enables complete conversion ... less than 6 hours. The highly ... against DNA degradation and a spin-column-based ... fast and reliable results for all ...
Biology Products: